Skip to main content
77°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunogen Inc
(NQ:
IMGN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunogen Inc
< Previous
1
2
3
4
5
Next >
ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading
February 08, 2024
Via
Investor Brand Network
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
ImmunoGen, Inc.
Via
Business Wire
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
Via
Get News
Exposures
Product Safety
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug...
Via
TheNewswire.com
Exposures
Product Safety
ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading
November 30, 2023
Via
Investor Brand Network
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2024
From
ImmunoGen, Inc.
Via
Business Wire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
AbbVie continues shopping spree with biotech buyout
December 12, 2023
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend.
Via
MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
December 11, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
December 10, 2023
From
ImmunoGen Inc.
Via
Business Wire
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
December 05, 2023
From
ImmunoGen, Inc.
Via
Business Wire
IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN
December 04, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
December 04, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
IMGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to Shareholders
November 30, 2023
From
Halper Sadeh LLC
Via
Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
November 02, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
November 02, 2023
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2023
From
ImmunoGen, Inc.,
Via
Business Wire
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
October 27, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results
October 19, 2023
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
September 28, 2023
From
ImmunoGen Inc.
Via
Business Wire
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
September 20, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress...
Via
FinancialNewsMedia
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
September 18, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
August 28, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
July 31, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
July 31, 2023
From
ImmunoGen, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.